Waters Corporation

CEO Dr. Udit Batra has refocused the portfolio on large‑molecule workflows and executed product and commercial initiatives that improved service attachment and instrument replacement cycles. CFO Amol Chaubal provides continuity and will serve as CFO of the combined company post‑RMT.

Execution in 2025 included raising sales and EPS guidance on multiple quarters. Risks: the BD combination’s scale increases integration demands; governance adds BD board designees at close. Overall, management quality, communication, and operating cadence are strong.